Despite this promising therapeutic potential, pathogenic POLE mutations are found in only 1–2% of CRC cases, and their detection requires advanced molecular techniques such as polymerase chain reaction (PCR), Sanger sequencing, and next-generation sequencing (NGS) [9,10]. This evidence concerns the gene POLE and colorectal carcinoma.